48
Participants
Start Date
January 11, 2024
Primary Completion Date
July 1, 2026
Study Completion Date
October 8, 2026
GLB-001
Administered orally according to the assigned treatment schedule
RECRUITING
Memorial Sloan Kettering Cancer Center-David H. Koch Center, New York
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
TERMINATED
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
University of Kansas Medical Center Research Institute, Inc., Kansas City
TERMINATED
Alliance for Multispecialty Research, LLC, Merriam
RECRUITING
University of Texas M. D. Anderson Cancer Center, Houston
RECRUITING
City of Hope Medical Center, Duarte
TERMINATED
University of California Irvine, Irvine
Lead Sponsor
GluBio Therapeutics Inc.
INDUSTRY